Discovery and Structure-activity Relationships (SAR) of a Novel Class of 2-substituted N-piperidinyl Indole-based Nociceptin Opioid Receptor Ligands

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2023 Aug 13

PMID 37573822

Authors

Michael E Meyer

Arpit Doshi

Willma E Polgar

Nurulain T Zaveri

Affiliations

Soon will be listed here.

Abstract

The development of SAR around substituted N-piperidinyl indole-based nociceptin opioid receptor (NOP) ligands led to the discovery of a novel series of 2-substituted N-piperidinyl indoles that provide both selective NOP full agonists and bifunctional NOP full agonists-μ opioid (MOP) receptor partial agonists. 2-substituted N-piperidinyl indoles have improved potency at the NOP receptor and are NOP full agonists, compared to our previously reported 3-substituted N-piperidinyl indoles that are selective NOP partial agonists. SAR in this series of 2-substituted N-piperidinyl indoles shows that 2-substitution versus 3-substitution on the indole moiety affects their intrinsic activity and opioid receptor selectivity. Molecular docking of these 2-substituted N-piperidinyl indoles in an active-state NOP homology model and MOP receptor structures provides a rationale for the differences observed in the binding, functional profiles and selectivity of 2-substituted versus 3-substituted N-piperidinyl indoles.

References

Meunier J, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P . Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377(6549):532-5. DOI: 10.1038/377532a0. View

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisano C, Morella I . Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. Br J Pharmacol. 2017; 175(5):782-796. PMC: 5811622. DOI: 10.1111/bph.14123. View

Sandin J, Georgieva J, Schott P, Ogren S, Terenius L . Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci. 1997; 9(1):194-7. DOI: 10.1111/j.1460-9568.1997.tb01367.x. View

Gavioli E, de Medeiros I, Monteiro M, Calo G, Romao P . Nociceptin/orphanin FQ-NOP receptor system in inflammatory and immune-mediated diseases. Vitam Horm. 2015; 97:241-66. DOI: 10.1016/bs.vh.2014.11.003. View

Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak C . Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 1994; 347(2-3):279-83. DOI: 10.1016/0014-5793(94)00560-5. View

Ciccocioppo R, Borruto A, Domi A, Teshima K, Cannella N, Weiss F . NOP-Related Mechanisms in Substance Use Disorders. Handb Exp Pharmacol. 2019; 254:187-212. PMC: 6641545. DOI: 10.1007/164_2019_209. View

Zaveri N, Marquez P, Meyer M, Polgar W, Hamid A, Lutfy K . A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice. Alcohol Clin Exp Res. 2017; 42(2):461-471. PMC: 5785446. DOI: 10.1111/acer.13575. View

Reinscheid R, Nothacker H, Bourson A, Ardati A, Henningsen R, Bunzow J . Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995; 270(5237):792-4. DOI: 10.1126/science.270.5237.792. View

El Daibani A, Che T . Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain. Molecules. 2022; 27(3). PMC: 8838650. DOI: 10.3390/molecules27030595. View

10.

Toll L, Khroyan T, Polgar W, Jiang F, Olsen C, Zaveri N . Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther. 2009; 331(3):954-64. PMC: 2784720. DOI: 10.1124/jpet.109.157446. View

11.

Meyer M, Doshi A, Yasuda D, Zaveri N . Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists. AAPS J. 2021; 23(3):68. DOI: 10.1208/s12248-021-00589-7. View

12.

Daga P, Zaveri N . Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation. Proteins. 2012; 80(8):1948-61. PMC: 3393802. DOI: 10.1002/prot.24077. View

13.

Zaveri N, Meyer M . NOP-Targeted Nonpeptide Ligands. Handb Exp Pharmacol. 2019; 254:37-67. DOI: 10.1007/164_2019_213. View

14.

Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N . cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 1994; 343(1):42-6. DOI: 10.1016/0014-5793(94)80603-9. View

15.

Journigan V, Polgar W, Khroyan T, Zaveri N . Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. Bioorg Med Chem. 2014; 22(8):2508-16. PMC: 4033624. DOI: 10.1016/j.bmc.2014.02.047. View

16.

Meng F, Taylor L, Hoversten M, Ueda Y, Ardati A, Reinscheid R . Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J Biol Chem. 1996; 271(50):32016-20. DOI: 10.1074/jbc.271.50.32016. View

17.

Kamakolanu U, Meyer M, Yasuda D, Polgar W, Marti M, Mercatelli D . Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models. J Med Chem. 2020; 63(5):2688-2704. DOI: 10.1021/acs.jmedchem.9b02134. View

18.

Ferrari F, Cerlesi M, Malfacini D, Asth L, Gavioli E, Journigan B . In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol. 2016; 793:1-13. PMC: 5555400. DOI: 10.1016/j.ejphar.2016.10.025. View

19.

Toll L, Bruchas M, Calo G, Cox B, Zaveri N . Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev. 2016; 68(2):419-57. PMC: 4813427. DOI: 10.1124/pr.114.009209. View

20.

Zaveri N . Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem. 2016; 59(15):7011-28. PMC: 5001850. DOI: 10.1021/acs.jmedchem.5b01499. View